Hemostemix Inc. (CVE:HEM – Get Free Report)’s share price was up 16.7% during trading on Wednesday . The stock traded as high as C$0.11 and last traded at C$0.11. Approximately 282,130 shares changed hands during mid-day trading, an increase of 296% from the average daily volume of 71,223 shares. The stock had previously closed at C$0.09.
Hemostemix Stock Performance
The stock has a market cap of C$9.15 million, a PE ratio of -5.25 and a beta of 0.15. The firm has a 50-day moving average price of C$0.06 and a 200-day moving average price of C$0.06.
Hemostemix Company Profile
Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions. The company develops cell therapy products from the patient's own blood, which is a non-invasive source of therapeutic cells. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia in Canada and the United States.
Further Reading
- Five stocks we like better than Hemostemix
- How Can Retail Investors Trade the Toronto Stock Exchange (TSX)?
- S&P 500 Hitting Resistance: These 3 Stocks Offer the Best Upside
- Business Services Stocks Investing
- Nike’s Post-Earnings Drop Presents a Buying Opportunity
- Financial Services Stocks Investing
- Microsoft’s Targeted Upside Might Be Too Good to Ignore
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.
